| Budesonide, Formoterol |
II-12855/ 17.04.2006 |
SYMBICORT TURBUHALER 320/9 MCG/INHALATION, Inhalation powder, 320 mcg/9 mcg/dose - 60 doses, IU, Pack: 1 |
AstraZeneca AB, Швеция |
AstraZeneca AB, Sweden; Corden Pharma GmbH, Germany |
60.63 |
12.13 |
72.76 |
4% |
2.43 |
63.06 |
12.61 |
75.67 |
16% |
9.7 |
72.76 |
14.55 |
87.31 |
Отхвърлена жалба от Комисия по прозрачност с решение КП-17/17.02.2015 |
НСР-4749/02.10.2014 |
16.03.2015 |
16.03.2015 |
Неактивен |
3615 |
| Budesonide, Formoterol |
II-12855/ 17.04.2006 |
SYMBICORT TURBUHALER 320/9 MCG/INHALATION, Inhalation powder, 320 mcg/9 mcg/dose - 60 doses, IU, Pack: 1 |
AstraZeneca AB, Швеция |
AstraZeneca AB, Sweden; Corden Pharma GmbH, Germany |
69.73 |
13.95 |
83.68 |
4% |
2.79 |
72.52 |
14.5 |
87.02 |
16% |
11.16 |
83.68 |
16.74 |
100.42 |
|
НСР-2283/13.01.2014 |
05.02.2014 |
05.02.2014 |
Неактивен |
3615 |
| Budesonide, Formoterol |
II-12855/ 17.04.2006 |
SYMBICORT TURBUHALER 320/9 MCG/INHALATION, Inhalation powder, 320 mcg/9 mcg/dose - 60 doses, IU, Pack: 1 |
AstraZeneca AB, Швеция |
AstraZeneca AB, Sweden; Corden Pharma GmbH, Germany |
71.86 |
14.37 |
86.23 |
4% |
2.87 |
74.73 |
14.95 |
89.68 |
16% |
11.5 |
86.23 |
17.25 |
103.48 |
оттеглена жалба от Комисия по прозрачност с решение КП-180/10.04.2013 |
КЦРР-925/04.07.2012 |
24.04.2013 |
24.04.2013 |
Неактивен |
3615 |
| Budesonide, Formoterol |
II-12855/ 17.04.2006 |
SYMBICORT TURBUHALER 320/9 MCG/INHALATION, Inhalation powder, 320 mcg/9 mcg/dose - 60 doses, IU, Pack: 1 |
AstraZeneca AB, Швеция |
AstraZeneca AB, Sweden; Corden Pharma GmbH, Germany |
79.43 |
15.89 |
95.32 |
4% |
3.18 |
82.61 |
16.52 |
99.13 |
16% |
12.71 |
95.32 |
19.06 |
114.38 |
|
КЦ-389/07.01.2009 |
26.01.2009 |
26.01.2009 |
Неактивен |
3615 |
| Emtricitabine, tenofovir alafenamide, darunavir and cobicistat |
EU/1/17/1225/001 |
Symtuza, Film coated tablet, 800 mg/150 mg/200 mg/10 mg, -, Pack: 30 |
Janssen-Cilag International N.V., Белгия |
Janssen-Cilag SpA, Италия |
1457.09 |
291.42 |
1748.51 |
4% |
10 |
1467.09 |
293.42 |
1760.51 |
16% |
25 |
1492.09 |
298.42 |
1790.51 |
|
НСР-20091/31.10.2019 Предварително изпълнение; НСР-21675/11.06.2020 |
26.06.2020 |
02.07.2020 |
Активен |
16746 |
| Emtricitabine, tenofovir alafenamide, darunavir and cobicistat |
EU/1/17/1225/001 |
Symtuza, Film coated tablet, 800 mg/150 mg/200 mg/10 mg, -, Pack: 30 |
Janssen-Cilag International N.V., Белгия |
Janssen-Cilag SpA, Италия |
1458.05 |
291.61 |
1749.66 |
4% |
10 |
1468.05 |
293.61 |
1761.66 |
16% |
25 |
1493.05 |
298.61 |
1791.66 |
|
НСР-20091/31.10.2019 Предварително изпълнение |
31.10.2019 |
02.11.2019 |
Неактивен |
16746 |
| darunavir, cobicistat, emtricitabine and tenofovir alafenamide |
|
Symtuza, Film coated tablet, 800 mg/150 mg/200 mg/10 mg, -, Pack: 30 |
Janssen-Cilag International N.V., Белгия |
JanssenCilag SpA, Италия |
1458.05 |
291.61 |
1749.66 |
4% |
10 |
1468.05 |
293.61 |
1761.66 |
16% |
25 |
1493.05 |
298.61 |
1791.66 |
|
НСР-20091/31.10.19 - с предварително изпълнение |
31.10.2019 |
02.11.2019 |
Неактивен |
16746 |
| Palivizumab |
EU/1/99/117/003 |
Synagis, Solution for injection, 50 mg/0,5 ml, -, Pack: 1 vial |
AbbVie Deutschland GmbH & Co. KG, Германия |
AbbVie S.r.l., Италия |
789.06 |
157.81 |
946.87 |
4% |
10 |
799.06 |
159.81 |
958.87 |
16% |
25 |
824.06 |
164.81 |
988.87 |
Промяна на обстоятелствата НСР-16389/02.08.2018 |
НСР-5511/29.01.2015; НСР-10448/29.09.2016; НСР-15739/25.05.2018 |
09.06.2018 |
02.09.2020 |
Активен |
3526 |
| Palivizumab |
EU/1/99/117/001 |
Synagis, Powder and solvent for solution for injection, 50, mg, Pack: 1 |
AbbVie Ltd, Обединено Кралство |
AbbVie S.r.l, Campoverde di Aprilia(Latina), Италия |
799.99 |
160 |
959.99 |
4% |
10 |
809.99 |
162 |
971.99 |
16% |
25 |
834.99 |
167 |
1001.99 |
|
НСР-7126/24.09.2015; НСР-9322/16.05.2016 |
02.07.2016 |
02.07.2016 |
Заличен |
3109 |
| Palivizumab |
EU/1/99/117/001 |
Synagis, Powder and solvent for solution for injection, 50, mg, Pack: 1 |
AbbVie Ltd, Обединено Кралство |
AbbVie S.r.l, Campoverde di Aprilia(Latina), Италия |
799.99 |
160 |
959.99 |
4% |
10 |
809.99 |
162 |
971.99 |
16% |
25 |
834.99 |
167 |
1001.99 |
|
НСР-7126/24.09.2015 |
10.10.2015 |
10.10.2015 |
Неактивен |
3109 |
| Palivizumab |
EU/1/99/117/001 |
Synagis, Powder and solvent for solution for injection, 50, mg, Pack: 1 |
AbbVie Ltd, Обединено Кралство |
AbbVie S.r.l, Campoverde di Aprilia(Latina), Италия |
837.27 |
167.45 |
1004.72 |
4% |
10 |
847.27 |
169.45 |
1016.72 |
16% |
25 |
872.27 |
174.45 |
1046.72 |
|
НСР-4321/05.08.2014 |
20.08.2014 |
20.08.2014 |
Неактивен |
3109 |
| Palivizumab |
EU/1/99/117/001 |
Synagis, Powder and solvent for solution for injection, 50, mg, Pack: 1 |
AbbVie Ltd, Обединено Кралство |
AbbVie S.r.l, Campoverde di Aprilia(Latina), Италия |
851.43 |
170.29 |
1021.72 |
4% |
10 |
861.43 |
172.29 |
1033.72 |
16% |
25 |
886.43 |
177.29 |
1063.72 |
промяна на обстоятелства НСР-2664/03.02.2014- допуска предварителн изпълнение НСР-2812/21.02.2014 |
НСР-1645/11.11.2013 |
04.12.2013 |
04.12.2013 |
Неактивен |
3109 |
| Palivizumab |
EU/1/99/117/001 |
Synagis, Powder and solvent for solution for injection, 50, mg, Pack: 1 |
AbbVie Ltd, Обединено Кралство |
Abbot Laboratories S.r.l, Campoverde, Италия |
913.43 |
182.69 |
1096.12 |
4% |
10 |
923.43 |
184.69 |
1108.12 |
16% |
25 |
948.43 |
189.69 |
1138.12 |
промяна на обстоятелства решение НСР-498/11.07.2013 |
КЦ-453/21.01.2009 |
12.02.2009 |
12.02.2009 |
Неактивен |
3109 |
| Palivizumab |
EU/1/99/117/003 |
Synagis, Solution for injection, 100 mg/ml, mg, Pack: 0.5 ml x 1 vial |
AbbVie Deutschland GmbH & Co. KG, Германия |
AbbVie S.r.l., Италия |
789.06 |
157.81 |
946.87 |
4% |
10 |
799.06 |
159.81 |
958.87 |
16% |
25 |
824.06 |
164.81 |
988.87 |
Промяна на обстоятелствата НСР-16389/02.08.2018 |
НСР-5511/29.01.2015; НСР-10448/29.09.2016; НСР-15739/25.05.2018 |
09.06.2018 |
02.09.2018 |
Неактивен |
3526 |
| Palivizumab |
EU/1/99/117/003 |
Synagis, Solution for injection, 100 mg/ml, mg, Pack: 0.5 ml x 1 vial |
AbbVie Deutschland GmbH & Co. KG, Германия |
AbbVie S.r.l., Италия |
789.06 |
157.81 |
946.87 |
4% |
10 |
799.06 |
159.81 |
958.87 |
16% |
25 |
824.06 |
164.81 |
988.87 |
Промяна на обстоятелствата НСР-16389/02.08.2018 |
НСР-5511/29.01.2015; НСР-10448/29.09.2016; НСР-15739/25.05.2018 |
09.06.2018 |
02.09.2018 |
Неактивен |
3526 |
| Palivizumab |
EU/1/99/117/003 |
Synagis, Solution for injection, 100 mg/ml, mg, Pack: 0.5 ml x 1 vial |
AbbVie Ltd, Обединено Кралство |
AbbVie S.r.l., Италия |
789.06 |
157.81 |
946.87 |
4% |
10 |
799.06 |
159.81 |
958.87 |
16% |
25 |
824.06 |
164.81 |
988.87 |
|
НСР-5511/29.01.2015; НСР-10448/29.09.2016; НСР-15739/25.05.2018 |
09.06.2018 |
02.07.2018 |
Неактивен |
3526 |
| Palivizumab |
EU/1/99/117/003 |
Synagis, Solution for injection, 100 mg/ml, mg, Pack: 0.5 ml x 1 vial |
AbbVie Ltd, Обединено Кралство |
AbbVie S.r.l., Италия |
796.82 |
159.36 |
956.18 |
4% |
10 |
806.82 |
161.36 |
968.18 |
16% |
25 |
831.82 |
166.36 |
998.18 |
|
НСР-5511/29.01.2015; НСР-10448/29.09.2016 |
14.10.2016 |
02.11.2016 |
Неактивен |
3526 |
| Palivizumab |
EU/1/99/117/003 |
Synagis, Solution for injection, 100 mg/ml, mg, Pack: 0.5 ml x 1 vial |
AbbVie Ltd, Обединено Кралство |
AbbVie S.r.l., Италия |
837.27 |
167.45 |
1004.72 |
4% |
10 |
847.27 |
169.45 |
1016.72 |
16% |
25 |
872.27 |
174.45 |
1046.72 |
|
НСР-5511/29.01.2015 |
12.02.2015 |
12.02.2015 |
Неактивен |
3526 |
| Nafarelin |
II-14140/16.08.2006 |
Synarel, Nasal spray, solution, 2, mg, Pack: 8 |
Pfizer Europe MA EEIG, Обединено Кралство |
NPIL Pharmaceuticals (UK) Ltd.
Morpeth Plant
Whalton Road,
Morpeth, Northumberland,
NE61 3YA
United Kingdom |
218.13 |
43.63 |
261.76 |
4% |
8.73 |
226.86 |
45.37 |
272.23 |
16% |
25 |
251.86 |
50.37 |
302.23 |
Цената се заличава с решение НСР-2231/20.12.2013 |
КЦ-3173/04.11.2011 |
06.03.2013 |
06.03.2013 |
Заличен |
1637 |
| Nafarelin |
II-14140/16.08.2006 |
Synarel, Nasal spray, solution, 2, mg, Pack: 8 |
Pfizer Europe MA EEIG, Обединено Кралство |
NPIL Pharmaceuticals (UK) Ltd.
Morpeth Plant
Whalton Road,
Morpeth, Northumberland,
NE61 3YA
United Kingdom |
219.05 |
43.81 |
262.86 |
4% |
8.76 |
227.81 |
45.56 |
273.37 |
16% |
25 |
252.81 |
50.56 |
303.37 |
|
КЦ-707/09.03.2009 |
25.03.2009 |
25.03.2009 |
Неактивен |
1637 |
| Nafarelin |
II-14140/16.08.2006 |
Synarel, Nasal spray, solution, 2, mg, Pack: 4 |
Pfizer Europe MA EEIG, Обединено Кралство |
NPIL Pharmaceuticals (UK) Ltd.
Morpeth Plant
Whalton Road,
Morpeth, Northumberland,
NE61 3YA
United Kingdom |
98.93 |
19.79 |
118.72 |
4% |
3.96 |
102.89 |
20.58 |
123.47 |
16% |
15.83 |
118.72 |
23.74 |
142.46 |
Цената се заличава с решение НСР-2231/20.12.2013 |
КЦ-3173/04.11.2011 |
06.03.2013 |
06.03.2013 |
Заличен |
1636 |
| Nafarelin |
II-14140/16.08.2006 |
Synarel, Nasal spray, solution, 2, mg, Pack: 4 |
Pfizer Europe MA EEIG, Обединено Кралство |
NPIL Pharmaceuticals (UK) Ltd.
Morpeth Plant
Whalton Road,
Morpeth, Northumberland,
NE61 3YA
United Kingdom |
109.53 |
21.91 |
131.44 |
4% |
4.38 |
113.91 |
22.78 |
136.69 |
16% |
17.52 |
131.43 |
26.29 |
157.72 |
|
КЦ-707/09.03.2009 |
25.03.2009 |
25.03.2009 |
Неактивен |
1636 |
| Pneumococcus purified polysaccharides antigen and haemophilus influenzae, conjugated |
EU/1/09/508/003 |
Synflorix, Suspension for injection, Combination, съгл. посоченото съдържание в КХП, -, Pack: 1 |
GlaxoSmithKline Biologicals S.A., Белгия |
GlaxoSmithKline Biologicals SA, Belgium |
62.59 |
12.52 |
75.11 |
4% |
2.5 |
65.09 |
13.02 |
78.11 |
16% |
10.01 |
75.1 |
15.02 |
90.12 |
|
НСР-1281/25.09.2013 |
10.10.2013 |
10.10.2013 |
Неактивен |
2958 |
| Pneumococcus purified polysaccharides antigen and haemophilus influenzae, conjugated |
EU/1/09/508/003 |
Synflorix, Suspension for injection, Combination, съгл. посоченото съдържание в КХП, -, Pack: 1 |
GlaxoSmithKline Biologicals S.A., Белгия |
GlaxoSmithKline Biologicals SA, Belgium |
107.57 |
21.51 |
129.08 |
4% |
4.3 |
111.87 |
22.37 |
134.24 |
16% |
17.21 |
129.08 |
25.82 |
154.9 |
|
КЦ-883/18.05.2009 |
01.06.2009 |
01.06.2009 |
Неактивен |
2958 |
| Pneumococcal polysaccharide conjugate vaccine (adsorbed) |
EU/1/ 09/508 /005 |
SYNFLORIX, Suspension for injection, 0.5, ml, Pack: 1 prefilled syringe + 2 needles |
GlaxoSmithKline Biologicals S.A., Белгия |
GlaxoSmithKline Biologicals S.A., Белгия |
61.57 |
12.31 |
73.88 |
4% |
2.46 |
64.03 |
12.81 |
76.84 |
16% |
9.85 |
73.88 |
14.78 |
88.66 |
|
НСР-16866/28.09.2018 |
13.10.2018 |
02.11.2018 |
Активен |
16291 |